These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32157296)

  • 1. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
    Ko TK; Javed A; Lee KL; Pathiraja TN; Liu X; Malik S; Soh SX; Heng XT; Takahashi N; Tan JHJ; Bhatia R; Khng AJ; Chng WJ; Sia YY; Fruman DA; Ng KP; Chan ZE; Xie KJ; Hoi Q; Chan CX; Teo ASM; Velazquez Camacho O; Meah WY; Khor CC; Ong CTJ; Soon WJW; Tan P; Ng PC; Chuah C; Hillmer AM; Ong ST
    Blood; 2020 Jun; 135(26):2337-2353. PubMed ID: 32157296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of expression of both miR-15/16 loci in CML transition to blast crisis.
    Lovat F; Gasparini P; Nigita G; Larkin K; Byrd JC; Minden MD; Andreeff M; Carter BZ; Croce CM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of EZH2 gene mutation in chronic myeloid leukemia patients in blast crisis.
    Chen HY; Yao H; Wu LY; Liu CJ; Zhu JQ; Liu CH; Wang W; Dong SS; Ping NN; Chen SN; Sun M
    Asian Pac J Cancer Prev; 2013; 14(5):3375-6. PubMed ID: 23803132
    [No Abstract]   [Full Text] [Related]  

  • 7. Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.
    Kazemi-Sefat GE; Keramatipour M; Vaezi M; Razavi SM; Kavousi K; Talebi A; Rostami S; Yaghmaie M; Chahardouli B; Talebi S; Mousavizadeh K
    Sci Rep; 2022 Jul; 12(1):12816. PubMed ID: 35896598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
    Abrahamsson AE; Geron I; Gotlib J; Dao KH; Barroga CF; Newton IG; Giles FJ; Durocher J; Creusot RS; Karimi M; Jones C; Zehnder JL; Keating A; Negrin RS; Weissman IL; Jamieson CH
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3925-9. PubMed ID: 19237556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
    Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
    Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
    Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
    Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
    Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
    Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.
    Xie H; Peng C; Huang J; Li BE; Kim W; Smith EC; Fujiwara Y; Qi J; Cheloni G; Das PP; Nguyen M; Li S; Bradner JE; Orkin SH
    Cancer Discov; 2016 Nov; 6(11):1237-1247. PubMed ID: 27630126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing.
    Huang Y; Zheng J; Hu JD; Wu YA; Zheng XY; Liu TB; Chen FL
    Genet Mol Res; 2014 Feb; 13(1):945-53. PubMed ID: 24634115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.
    Matte-Martone C; Venkatesan S; Tan HS; Athanasiadis I; Chang J; Pavisic J; Shlomchik WD
    J Immunol; 2011 Aug; 187(4):1653-63. PubMed ID: 21768400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.
    Ochi Y; Yoshida K; Huang YJ; Kuo MC; Nannya Y; Sasaki K; Mitani K; Hosoya N; Hiramoto N; Ishikawa T; Branford S; Shanmuganathan N; Ohyashiki K; Takahashi N; Takaku T; Tsuchiya S; Kanemura N; Nakamura N; Ueda Y; Yoshihara S; Bera R; Shiozawa Y; Zhao L; Takeda J; Watatani Y; Okuda R; Makishima H; Shiraishi Y; Chiba K; Tanaka H; Sanada M; Takaori-Kondo A; Miyano S; Ogawa S; Shih LY
    Nat Commun; 2021 May; 12(1):2833. PubMed ID: 33990592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia.
    Bhattacharyya J; Mihara K; Yasunaga S; Tanaka H; Hoshi M; Takihara Y; Kimura A
    Ann Hematol; 2009 Apr; 88(4):333-40. PubMed ID: 18781299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.